December 17, 2014 3:38 PM ET

Healthcare Equipment and Supplies

Company Overview of OrbusNeich Medical Company Limited

Company Overview

OrbusNeich Medical Company Limited designs, develops, manufactures, and markets medical devices for the treatment of vascular diseases. The company offers dual therapy, bare metal, pro-healing, bio-engineered R, and bio-engineered cobalt chromium stents; and other stents and balloons. It serves interventional cardiologists and physicians in Hong Kong and internationally through its predecessor companies, sales teams, and a distributor network. The company was formerly known as Neich Medical Company Limited and changed its name to OrbusNeich Medical Company Limited following its merger with Orbus Medical Technologies, Inc. in January 2005. The company was founded in 1979 and is headquartered ...

13th Floor

Harcourt House

39 Gloucester Road

Wanchai,  1102

Hong Kong

Founded in 1979


852 2802 2288


852 2507 3532

Key Executives for OrbusNeich Medical Company Limited

Chief Executive Officer
Chairman of The Board and Executive in Charge of Asia Pacific
Age: 49
Chief Financial Officer
Vice President of Sales and Marketing of EMEA and Director
Compensation as of Fiscal Year 2014.

OrbusNeich Medical Company Limited Key Developments

OrbusNeich Appoints B. Wayne Johnson as President and Chief Executive Officer

OrbusNeich announced the appointment of B. Wayne Johnson as president and chief executive officer (CEO), with responsibility for all commercial and clinical aspects of the company. Mr. Johnson, who has more than 32 years of medical device experience, will continue placing a heavy emphasis on research and development, cementing OrbusNeich's reputation as an innovative, forward-looking leader in interventional cardiology. Johnson joined OrbusNeich in 2002 and most recently has served in the role of president and chief operating officer.

OrbusNeich Announces Executive Changes

OrbusNeich announced the appointment of B. Wayne Johnson as president and chief operating officer and the expansion of its board of directors with the additions of Scott Addonizio, vice president & general manager, Shenzhen operations; David Camp, vice president, sales & marketing, Europe, the Middle East and Africa (EMEA); and Christophe Lee, vice president and chief financial officer. Mr. Johnson has more than 32 years of medical device experience, primarily in the areas of general management, operations and product development. He was previously senior vice president and chief operating officer of OrbusNeich.

OrbusNeich Launches New Coronary Dilatation Catheter

OrbusNeich has launched Sapphire II NC coronary dilatation catheter, a non-compliant balloon catheter to cross tight lesions. Sapphire II NC's proprietary balloon processing results in crossing profile for primary and repeated lesion entry. The enhanced distal Z-Tip with advanced laser welding technology results in ZERO transition between the distal tip and conventional steerable guidewires. Sapphire II NC is available in a broad range of sizes, from 1.75 mm to 5 mm, with a catheter working length of 140 cm.

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OrbusNeich Medical Company Limited, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at